Strengthening Induction Therapy for Aggressive B-Cell Lymphoma

Clinical Takeaway

: Adding glofitamab to R-CHOP or Pola-R-CHP yielded a response rate of 100% in younger patients with high-risk large B-cell lymphoma.

Context

Glofitamab is a bispecific T-cell engaging monoclonal antibody with single-agent activity in relapsed or refractory large B-cell lymphoma (LBCL). Now, investigators have assessed the safety and efficacy of combining glofitamab with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) or Pola-R-CHP (polatuzumab, rituximab, cyclophosphamide, doxorubicin, and prednisone) in patients with high-risk international prognostic index scores, double-hit (DH) LBCL, or both. Glofitamab was initiated with stepped-up dosing in cycle 2; after completing induction chemotherapy, an additional two cycles of single-agent glofitamab were given. The primary endpoint was safety; response and survival outcomes were secondary endpo…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee